

Ref. No: FOI2026
Date: 03/09/2025
Subject: Biologics (Dermatology)

REQUEST

1. How many patients were treated in the last 3 months by the Dermatology department (for any medical condition) with the following biologic drugs:

- Adalimumab - Humira
- Adalimumab Biosimilar
- Apremilast
- Bimekizumab
- Brodalumab
- Certolizumab
- Deucravacitinib
- Dimethyl fumarate
- Etanercept - Enbrel
- Etanercept Biosimilar
- Guselkumab
- Infliximab - Remicade
- Infliximab Biosimilar
- Ixekizumab
- Risankizumab
- Secukinumab
- Tildrakizumab
- Ustekinumab - Stelara
- Ustekinumab Biosimilar
- Spesolimab

RESPONSE

MWL Response

- Adalimumab – Humira - 9
- Adalimumab Biosimilar - 88
- Apremilast - 79
- Bimekizumab - <5
- Brodalumab - 0
- Certolizumab - <5
- Deucravacitinib - 0

- Dimethyl fumarate - 9
- Etanercept – Enbrel - 0
- Etanercept Biosimilar - 0
- Guselkumab - 36
- Infliximab – Remicade - 0
- Infliximab Biosimilar - <5
- Ixekizumab - 12
- Risankizumab - 16
- Secukinumab - 6
- Tildrakizumab 0
- Ustekinumab – Stelara - 7
- Ustekinumab Biosimilar - 20
- Spesolimab - 0